LDOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Leidos Holdings Inc (LDOS) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has positive financial growth trends and recent strategic partnerships, the technical indicators and mixed analyst ratings suggest a cautious approach. The stock's pre-market price increase is modest, and there are no strong proprietary trading signals to support immediate action.
The MACD is positive at 0.685, indicating a bullish momentum, but it is contracting. RSI is neutral at 45.365, showing no clear overbought or oversold conditions. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot level of 156.889, with resistance at 161.049 and support at 152.729. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Hedge funds are significantly increasing their positions, with a 348.79% increase in buying activity last quarter.
Recent joint ventures and mergers, such as the partnership with Altaris and the merger with Analogic, aim to enhance global security and market competitiveness.
Positive financial performance in Q4 2025, with a 15.14% YoY increase in net income and a 20.57% YoY increase in EPS.
Analysts have lowered price targets, with concerns about growth challenges and risks in high-margin health work.
Revenue dropped by 3.62% YoY in Q4 2025, indicating potential headwinds in certain segments.
Mixed technical indicators and bearish moving averages suggest caution.
In Q4 2025, Leidos reported a revenue decline of 3.62% YoY to $4.21B. However, net income increased by 15.14% YoY to $327M, and EPS grew by 20.57% YoY to 2.52. Gross margin also improved by 10.64% YoY to 17.57%, reflecting operational efficiency.
Analysts have mixed views on LDOS. Jefferies maintains a Buy rating with a reduced price target of $185, citing support for growth estimates. Wells Fargo initiated coverage with an Equal Weight rating and a $165 price target, expressing concerns about diversification and health segment risks. Other firms have also lowered price targets, reflecting cautious sentiment.
